Protein expression of p53, p21(WAF1), and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 555-564

  Naka, Takuji ^a   Toyota, Nobuhiko ^a   Kaneko, Tetsuya ^a   Kaibara, Nobuaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; p21(WAF1); p53; Rb

Indexed keywords

MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADOLESCENT; ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; PROGNOSIS; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031948753     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuti S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo QL, Houghton M, and Kuo G: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci(Wash.) 87: 6547-6549, 1990.
2. Simonetti RG, Camma C, Fiorello F, Politi F, D'amico G, and Pagliaro L: Hepatocellular carcinoma: a worldwide problem and the major risk factors. Dig Dis Sci 36: 962-972, 1991.
3. Tanaka K, Hirohata T, Koga S, Sugimachi K, Kanematsu T, Ohryohji F, Nawata H, Ishibashi H, Maeda Y, Kiyokawa H, Tokunaga K, Irita Y, Takashita S, Arase Y, and Nishino N: Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res 51: 2842-2847, 1991.
4. Fearon ER, and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
5. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
6. Murakami Y, Hayashi K, Hirohashi S, and Sekiya T: Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas: Cancer Res 51: 5520-5525, 1991.
7. Michalovitz D, Halevy O, and Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant p53. Cell 62: 671-680, 1990.
8. Lowe SW, Schmitt EM, Smith SW, Osborne BA, and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
9. EI-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
10. 1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
11. Serrano M, Hannon GJ, and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature(Lond.). 366: 704-707, 1993.
12. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
13. Serrano M, Gomez-Lahoz E, Depinho RA, Beach D, and Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16. Science(Washington DC) 267: 249-252, 1995.
14. Levine AJ, Momand J, and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
15. Horowitz JM, Park S-H, Bogenmann E, Cheng J-C, Yandell DW, Kaye FJ, Minna JD, Dryja TP, and Weinberg RA: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci 87: 2775-2779, 1990.
16. 1-S transition in clinical breast cancer tissue. Breast Cancer (in press), 1996.
17. Liver Cancer Study Group of Japan, The General Rules for the Clinical and Pathological Study of Primary Liver Cancer (The 3rd Edition). Kanehara Press, Tokyo, 1992.
18. Nagao T, Kondo F, Sato T, Nagato Y, and Kondo Y: Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma. Hum Pathol 26: 326-333, 1995.
19. Nose H, Imazeki F, Ohto M, and Omata M: p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer 72: 355-360, 1993.
20. 1 arrest in human cancer cell. Cancer Res 55: 5187-5190, 1995.
21. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919, 1995.
22. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, and Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395, 1994.
23. Jiang H, Lin J, Su Z-Z, Collart FR, Huberman E, and Fisher PB: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9: 3397-3406, 1994.
24. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, and Wang X-F: Transforming growth facter βinduces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sei 92: 5545-5549, 1995
25. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, Chella A, Merlo G, Angeletti CA, Palma PD, and Bevilacqua G: p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12: 1319-1324, 1996.
26. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, and Hruban RH: p53-independent expression of the cycle-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 147: 884-888, 1995.
27. Sheikh MS, Li XS, Cheo JC, Shao ZM, Ordonez JV, and Fontana JA: Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407-3415, 1994.
28. WAF1/CIP1 in human brain tumors. Oncogene 11: 2021-2029, 1995.
29. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, and Ozturk M: Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 7: 1407-1413, 1993.
30. Seki S, Kawakita N, Yanai Y, Kitada T, Sakai Y, Nakatani K, Yamada T, Sakaguchi H, and Kuroki T: Expression of the retinoblastoma gene product in human hepatocellular carcinoma. Hum Pathol 26: 366-374, 1995.
31. INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509, 1995.
32. INK4 expression in resected non-small cell lung tumors. Cancer Res 56: 3415-3420, 1996.
33. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 3: 313-319, 1997.
34. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, and Vousden KH: Specific loss of apoptotic but not cell cycle arrest function in a human tumor derived p53 mutant. EMBO J 15: 827-838, 1996.